Capstone Investment Advisors
TCRT icon

Capstone Investment Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Capstone Investment Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-103
Closed -$84K – 908
2016
Q2 		$84K Buy
+103
New +$112K ﹤0.01% 655

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capstone Investment Advisors's TCRT Position: Q3 2016 in Review

Capstone Investment Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2016, closing a stake of 103 shares — an estimated $84K sold.

Capstone Investment Advisors first reported a position in TCRT in Q2 2016 and held it in 1 quarter. The position peaked at $84K in Q2 2016. 140 funds tracked by Wall St. Rank hold TCRT as of Q3 2016.

  • Capstone Investment Advisors reported no remaining Alaunos Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Capstone Investment Advisors sold 103 Alaunos Therapeutics shares in Q3 2016, an estimated $84K.
  • Capstone Investment Advisors first reported a position in Alaunos Therapeutics in Q2 2016 and held it in 1 quarter.
  • Capstone Investment Advisors's Alaunos Therapeutics position peaked at $84K in Q2 2016.
  • 140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2016.

Based on Capstone Investment Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.